A 4.8 kDa, the VGF peptide was previously described as a potential biomarker of ALS as the levels were decreased in the CSF of ALS patients and distinguished them from controls (Pasinetti et al. 2006). This evidence concerns the gene VGF and amyotrophic lateral sclerosis.